Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 74 participants, all of whom received the study drug cediranib maleate. All 74 participants were recorded as having completed the study. The trial was measuring how the tumour responded to the treatment, using standard imaging-based criteria (known as RECIST) as well as a blood marker called CA-125, and also tracking how long it took for the disease to progress and how long participants lived overall. The reported data shows that, for the primary outcome — whether participants experienced a complete response (tumour disappearing), partial response (tumour shrinking by 30% or more), or stable disease (tumour not growing significantly) — 9 out of 74 participants showed a response based on the RECIST criteria, while 0 participants showed a response based on the Rustin criteria (a separate method using the CA-125 blood marker). For the secondary outcomes, the reported median time to disease progression was 7.2 months in one measure and 3.7 months in another. The median progression-free survival (the length of time before the disease started worsening) was reported as 4.9 months, and the median overall survival was reported as 18.9 months. Among those who had a CA-125 blood marker response, the reported median duration of that response was 108 weeks. The data for side effects (toxicity) was not reported in the structured results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25895616) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (confirmed by lab testing) that has come back or stopped responding to initial treatment.
- You have previously been treated with a platinum-based chemotherapy drug before joining this trial.
- Your cancer can be measured on a scan, showing at least one visible area of disease, OR your cancer is detectable through a blood test called CA-125 showing elevated levels on two separate tests taken more than 2 weeks apart.
- You have received no more than one prior course of chemotherapy (first-line treatment only).
- Doctors expect you to live for more than 12 weeks.
- You are well enough to carry out basic daily activities (a doctor will assess this using a standard scale).
- Your blood counts, liver function, and kidney function all fall within acceptable levels (confirmed by blood tests).
- If you could become pregnant, you must have a negative pregnancy test before starting the trial and agree to use reliable contraception throughout.
- You are willing and able to understand and sign a consent form agreeing to take part.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have had chemotherapy, radiation therapy, or major surgery within the past 4 weeks (or 6 weeks for certain specific chemotherapy drugs), or you are still experiencing side effects from previous treatment.
- Your tumour has been classified as "borderline" or "low malignant potential" (a less aggressive type of tumour).
- You currently have a bowel blockage (bowel obstruction).
- You are currently taking part in another clinical trial or have done so within the past 30 days.
- Cancer has spread to your brain.
- You have had a serious allergic reaction to a drug that is chemically similar to the trial drug (AZD2171/cediranib maleate).
- A heart tracing test (ECG) shows a specific abnormality in your heart's electrical activity, or you have a family history of a condition called long QT syndrome.
- Urine tests on two separate occasions (at least 1 week apart) show a significant level of protein in your urine.
- You have uncontrolled high blood pressure, an active infection, serious heart problems, or a mental health or personal situation that could make it difficult to follow the trial requirements.
- You are pregnant or currently breastfeeding.
- You are HIV-positive and receiving combination antiretroviral therapy.
- A recent heart tracing test (ECG) taken within the last 14 days shows any significant abnormality.
- You have been assessed as having a severe level of heart failure (classified as Class III or IV by your doctor — Class II patients who are well controlled with treatment may still be considered with extra monitoring).
- You are currently taking certain medications that can affect your heart rhythm, as these cannot be used alongside the trial drug (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria
Other options
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.